Renal function preservation with the mTOR inhibitor, Everolimus, after lung transplant

Clinical Transplantation

Volumn 28, Issue 6, 2014, Pages 662-668

  Schneer, Sonia ^a   Kramer, Mordechai R ^a   Fox, Benjamin ^a   Rusanov, Viktoria ^a   Fruchter, Oren ^a   Rosengarten, Dror ^a   Bakal, Ilana ^a   Medalion, Benjamin ^b   Raviv, Yael ^a  

^a RABIN MEDICAL CENTER   (Israel)

^b Rabin   (Israel)

Author keywords

Creatinine clearance; Everolimus; Lung; Mammalian target of rapamycin inhibitors; Renal failure; Transplant

Indexed keywords

CALCINEURIN INHIBITOR; EVEROLIMUS; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT; MTOR PROTEIN, HUMAN; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; COHORT ANALYSIS; CREATININE CLEARANCE; DIARRHEA; DRUG BLOOD LEVEL; DRUG FATALITY; DRUG WITHDRAWAL; EDEMA; FEMALE; GRAFT RECIPIENT; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY FUNCTION; LUNG FUNCTION; LUNG TRANSPLANTATION; LYMPHANGIOLEIOMYOMATOSIS; MALE; MEDICAL RECORD REVIEW; NEOPLASM; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; PRURITUS; RETROSPECTIVE STUDY; ULCER; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; DRUG COMBINATION; FOLLOW UP; GLOMERULUS FILTRATION RATE; KIDNEY FUNCTION TEST; LUNG DISEASES; MIDDLE AGED; POSTOPERATIVE COMPLICATION; PROGNOSIS; RENAL INSUFFICIENCY; RISK FACTOR;

ADULT; AGED; CALCINEURIN INHIBITORS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FUNCTION TESTS; LUNG DISEASES; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; RISK FACTORS; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84901933485     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12353     Document Type: Article

References (20)

1. Paradela de la Morena M, De La Torre Bravos M, Prado RF et al. Chronic kidney disease after lung transplantation: incidence, risk factors, and treatment. Transplant Proc 2010: 42: 3217.
2. Goes NB, Colvin RB. Case 12-2007 - a 56-year-old woman with renal failure after heart-lung transplantation. N Engl J Med 2007: 356: 1657.
3. Snell GI, Westall GP. Immunosuppression for lung transplantation: evidence to date. Drugs 2007: 67: 1531.
4. Gullestad L, Mortensen SA, Eiskjær H et al. Two-year outcomes in thoracic transplant recipients after conversion to everolimus with reduced calcineurin inhibitor within a multicenter, open-label, randomized trial. Transplantation 2010: 90: 1581.
5. Roman A, Ussetti P, Zurbano F et al. A retrospective 12-month study of conversion to everolimus in lung transplant recipients. Transplant Proc 2011: 43: 2693.
6. Shitrit D, Rahamimov R, Gidon S et al. Use of sirolimus and low-dose calcineurin inhibitor in lung transplant recipients with renal impairment: results of a controlled pilot study. Kidney Int 2005: 67: 1471.
7. Vahid B, Marik PE. Pulmonary complications of novel antineoplastic agents for solid tumors. Chest 2008: 133: 528.
8. Pieri M, Miraglia N, Polichetti G, Tarantino G, Acampora A, Capone D. Analytical and pharmacological aspects of therapeutic drug monitoring of mTOR inhibitors. Curr Drug Metab 2011: 12: 253.
9. Zuckermann A, Manito N, Epailly E et al. Multidisciplinary insights on clinical guidance for the use of proliferation signal inhibitors in heart transplantation. J Heart Lung Transplant 2008: 27: 141.
10. de Pablo A, Santos F, Solé A et al. Recommendations on the use of everolimus in lung transplantation. Transplant Rev 2013: 27: 9.
11. International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2012: 31: 1045. Available from: http://www.ishlt.org/registries/heartLungRegistry.asp; [accessed 2012].
12. Gridelli C, Maione P, Rossi A. The potential role of mTOR inhibitors in non-small cell lung cancer. Oncologist 2008: 13: 139.
13. González-Vilchez F, de Prada JA, Castrillo C, Canteli A, Llano MF, Martín-Durán R. Predictors of long-term renal function after conversion to proliferation signal inhibitors in long-term heart transplant recipients. J Heart Lung Transplant 2011: 30: 552.
14. Masetti M, Montalti R, Rompianesi G et al. Early withdrawal of calcineurin inhibitors and everolimus monotherapy in de novo liver transplant recipients preserves renal function. Am J Transplant 2010: 10: 2252.
15. Arora S, Gude E, Sigurdardottir V et al. Improvement in renal function after everolimus introduction and calcineurin inhibitor reduction in maintenance thoracic transplant recipients: the significance of baseline glomerular filtration rate. J Heart Lung Transplant 2012: 31: 259.
16. Parada MT, Alba A, Sepúlveda C, Melo J. Long-term use of everolimus in lung transplant patients. Transplant Proc 2011: 43: 2313.
17. Vitko S, Tedesco H, Eris J et al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant 2004: 4: 626.
18. Vogelbacher R, Wittmann S, Braun A, Daniel C, Hugo C. The mTOR inhibitor everolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat. Transplantation 2007: 84: 1492.
19. Moro J, Almenar L, Martínez-Dolz L et al. mTOR inhibitors and their secondary effects in cardiac transplant recipients: a descriptive study. Transplant Proc 2007: 39: 2365.
20. Expósito V, de Prada JA, Gómez-Román JJ et al. Everolimus-related pulmonary toxicity in heart transplant recipients. J Heart Lung Transplant 2008: 27: 797.